Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 6/20 | 0.32 |
| ▸ | CES2 | O00748 | 4/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13246788 | 0.98 | CCR2 (0.47) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL9476266 | 0.80 | CCR2 (0.43) | CCR2IDH1 | |
| SCHEMBL9479868 | 0.80 | CCR2 (0.43) | CCR2IDH1 | |
| SCHEMBL9652423 | 0.80 | CCR2 (0.43) | CCR2IDH1 | |
| SCHEMBL17284890 | 0.80 | CCR2 (0.43) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL9477120 | 0.80 | CCR2 (0.43) | CCR2IDH1 | |
| SCHEMBL9476457 | 0.80 | CCR2 (0.43) | CCR2IDH1 | |
| SCHEMBL15177359 | 0.78 | CCR2 (0.44) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL836834 | 0.78 | CCR2 (0.44) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL18905948 | 0.77 | CYP4F2 (0.40) | CCR2IDH1DPP4FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8507647-B2 | Antibacterial agents for the treatment of gram positive infections | CUBIST PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CUBIST PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150337013-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CCR2 1240/4885IDH1 4657/4885DPP4 512/4885 |
| US-20100184649-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CCR2 1240/4885IDH1 4657/4885DPP4 512/4885 |
| US-20140073558-A1 | NOVEL ANTIBACTERIAL AGENTS FOR THE TREATMENT OF GRAM POSITIVE INFECTIONS | CLPP, CLPTM1, RPN1 | CCR2 1240/4885IDH1 4657/4885DPP4 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.